More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.

At the recent SEC meeting for analgesics and rheumatology held on February 25, 2025, the expert panel reviewed the ...

Axial involvement is present in approximately 25% of patients with PsA, with enthesitis, inflammatory bowel disease, and ...

Arthritis is one of the most common chronic conditions affecting millions of people worldwide. Yet, many fail to recognize ...

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Targeted screening and management strategies are needed in older patients with PsA to help mitigate their morbidity and ...

Christian Cottingham-Endter has quite a few chronic conditions that make staying active and eating right a challenge. One of them is psoriatic arthritis. But thanks ...

Steqeyma, a treatment for plaque psoriasis, Crohn's disease, active psoriatic arthritis and ulcerative colitis, is ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.